Defunct Company
Total Trials
4
As Lead Sponsor
0
As Collaborator
Total Enrollment
76
NCT03618641
CMP-001 in Combo With Nivolumab in Stage IIIB/C/D Melanoma Patients With Clinically Apparent Lymph Node Disease
Phase: Phase 2
Role: Collaborator
Start: Aug 8, 2018
Completion: Dec 31, 2023
NCT03507699
Combined Immunotherapy and Radiosurgery for Metastatic Colorectal Cancer
Phase: Phase 1
Start: Dec 15, 2018
Completion: May 25, 2022
NCT03983668
CMP-001 for Relapsed and Refractory Lymphoma
Phase: Phase 1/2
Start: Jan 31, 2020
Completion: Apr 8, 2025
NCT04401995
Study of TLR9 Agonist Vidutolimod (CMP-001) in Combination with Nivolumab Vs. Nivolumab
Start: Sep 2, 2020
Completion: Aug 16, 2024